N/A N=234 The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)
Hemorrhage
Primary: Hemostatic Success at 5 Minutes — 109; 103 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
Phase 3 N=325 Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries
Parenchymous Tissue Surgical Bleeding
Primary: Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start — 92.8; 80.5 Percent of subjects achieving hemostasis
N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
Phase 3 N=253 TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
Hemorrhage
Primary: Percentage of Participants With Intraoperative Hemostasis at Target Bleeding Site Within 3 Minutes — 80.7; 50.0; 87.5; 44.4 percentage of participants — p=<0.001
Phase 3 N=40 The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study
Hemorrhage · Soft Tissue Bleeding · Hepatic Parenchyma Bleeding
Primary: Absolute Time to Haemostasis (TTH) — 4.0; 4.0 Minutes
Phase 3 N=35 The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study
Controlling Mild to Moderate Bleeding During Surgery
Primary: Absolute Time to Hemostasis — 4.00 Minutes
Phase 2 N=33 A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
Hemostasis · General Surgery
Primary: To Evaluate the Safety of sFilm-FS Versus an Active-comparator (TACHOSIL®) When Used as Adjunct to Conventional Hemostatic Techniques During Elective Surgery Through…
Phase 4 N=150 EVARREST™ Fibrin Sealant Patch Post-Market Study
Hemorrhage · Soft Tissue Bleeding
Primary: Safety Parameter - Incidence of Thromboembolic Events — 2; 7 Participants
Phase 4 N=60 TissueLink Study During Multi-Level Spine Surgery
Low Back Pain
Primary: Hemoglobin Measurement g/dl — 66.2; 102.4 hemoglobin g/dl
Phase 2 N=18 Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
Phase 2 N=141 The Fibrin Patch Soft Tissue Study
Hemostasis
Primary: Proportion of Subjects Achieving Hemostatic Success — 98.3; 53.3; 98.0 percentage of success
Phase 3 N=103 Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries
Soft Tissue Surgical Bleeding
Primary: Percentage of Subjects Achieving Hemostasis Within 4 Minutes After Treatment Start — 82.8; 77.8 percentage of participants
Phase 3 N=40 The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study
Hemorrhage · Soft Tissue Bleeding
Primary: Absolute Time to Haemostasis — 4.0; 4.0 Minutes
N/A N=22 Surgicel Snow in Gynecological Surgery
Laparoscopic Hysterectomy
Primary: Change in Bleeding at Specified Time Intervals — 485.7; 199.1 seconds
N/A N=30 A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue
Non-emergent, Soft Tissue Procedures, Performed Via an Open Approach
Primary: Percent Success in Obtaining Hemostasis Following Veriset Hemostatic Patch Treatment — 29 participants — p=<0.0001
N/A N=482 Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®
Hemorrhage
Primary: Assessment of TachoSil® by the Surgeon With Respect to Handling, Utility and Satisfaction in the Operation, Documented Using 10 Point Numerical Rating Scales — 2.54…
N/A N=70 U.S. Study of Fibrocaps in Surgical Hemostasis
Postoperative Hemorrhage
Primary: Mean Time to Hemostasis (TTH) — 1.9; 4.8 minutes — p=<0.001
Phase 2 N=52 Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma
Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants
N/A N=50 Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery
Liver Disease
Primary: Median Time to Achieve Hemostasis Following Application of Study Treatment. — 1; 3 Minutes — p=<0.0001
Phase 3 N=102 The EVARREST® Fibrin Sealant Patch Liver Study
Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization — 48; 24 participants with hemostatic success — p=<.0001
N/A N=324 Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System
Blood Loss, Surgical
Primary: Number of Participants With Achievement of Hemostasis at 7 Minutes — 145; 149 Participants — p=0.005
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Phase 3 N=150 Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery
Bleeding
Primary: Percentage of Participants With Intra-operative Hemostasis at the Evaluation Site Within 3 Minutes After Application of the Randomized Treatment — 26.0; 18.0 percentage…
Phase 1 N=27 HEMOBLAST Pilot Clinical Investigation
Hemostasis
Primary: Mean Paired Kappa Statistic for the Assignment of SBSS Scores by 2 Investigators — 0.7754 Kappa statistic
N/A N=260 Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding
Bleeding Active
Primary: Number of Participants With Hemostasis Achieved at Target Bleeding Site Within 5 Minutes After Application — 94; 109; 32; 15 Participants
Phase 2 N=48 Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?
Clopidogrel
Primary: Bleeding-related Re-hospitalization — 1; 1 participants
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters